Ali A C, Mihas C C, Campbell J A
Hemosol Inc., Etobicoke, Ontario, Canada.
Clin Chem. 1997 Sep;43(9):1738-43.
The interferences of o-raffinose cross-linked hemoglobin (Hemolink) were examined and compared in two serum creatinine methods on the Hitachi 717 [Boehringer Mannheim (BMC) and Synermed] and in an enzymatic creatinine method on the Vitros 750 (Johnson & Johnson). Interference was considered significant when the change in creatinine concentration from the control exceeded the 95% confidence limits of each method. Significant interference was observed for the BMC/Hitachi 717 method with Hemolink > or = 5 g/L. No interference was observed for the Synermed/Hitachi 717 assay with Hemolink up to 30 g/L in normal samples and up to 50 g/L in samples with increased creatinine. No interference was observed for the Vitros 750 assay with Hemolink up to 50 g/L at both normal and increased concentrations of creatinine. Although the BMC/Hitachi 717 method was considered unacceptable, the Synermed/Hitachi 717 and the Vitros 750 methods allow accurate quantification of serum creatinine in the presence of Hemolink.
在日立717（分别采用勃林格殷格翰公司（BMC）和Synermed公司的方法）上的两种血清肌酐检测方法以及在Vitros 750（强生公司）上的一种酶法肌酐检测方法中，对邻棉子糖交联血红蛋白（Hemolink）的干扰进行了检测和比较。当肌酐浓度相对于对照的变化超出每种方法的95%置信区间时，即认为存在显著干扰。对于BMC/日立717方法，当Hemolink≥5 g/L时观察到显著干扰。对于Synermed/日立717检测，在正常样本中，Hemolink浓度高达30 g/L时未观察到干扰；在肌酐升高的样本中，Hemolink浓度高达50 g/L时也未观察到干扰。对于Vitros 750检测，在肌酐正常和升高浓度的情况下，Hemolink浓度高达50 g/L时均未观察到干扰。尽管BMC/日立717方法被认为不可接受，但Synermed/日立717和Vitros 750方法能够在存在Hemolink的情况下准确测定血清肌酐。
